Day Three Labs has announced that it will be researching a remedy for Parkinson’s Disease using cannabis. The research and innovation will be funded by CanNegev, the world’s first government-sponsored cannabis innovation incubator. “Research shows that cannabis has the ability to ease Parkinson’s symptoms in patients, but to date, no one has been able to…
CBD Tablet Maker Canntab Partners With Pharmacy Group
Toronto-based Canntab Therapeutics Ltd., a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announced last week that it has entered into an affiliate agreement with OnPharm–United, a 600-plus network of independent pharmacy owners throughout the Province of Ontario. OnPharm-United works to provide its members with the ability to maintain…
Clinical CBD Maker Corganics Adds Pharma Exec to Board
Dallas-based life sciences and clinical cannabinoid company Corganics announced Jeff Hartness has joined its board of directors. Hartness currently serves as a senior vice president at Bausch Health and brings more than 25 years of pharmaceutical and health care industry experience to Corganics. “Jeff’s successful and diverse background crosses all channels and segments of…
Study Finds Cannabinoids Ease Pain in Cancer Patients
HERZLIYA, Israel – An Israeli biomedical company that develops medical products based on cannabis and fungal extracts has reported study results which show that using mushroom compounds in conjunction with cannabinoids achieves an 80-100% reduction in pain sensation. The company, Cannabotech, also reported that adding defined concentrations of other cannabinoids allowed using lower concentrations of…
New Elixinol Sleep Aids Feature CBN
Hemp-derived CBD brand Elixinol launched two new innovative CBD products focused on supporting sleep. Elixinol’s Sleep Rapid Rest Liposome and Sleep Gummies are unique, melatonin-free options for consumers to support optimal sleep. Both products include CBN, marking a first for the brand to include a minor cannabinoid into product formulations. The new product additions…
First Patient Set for Alzheimer’s Clinical Trial Using Delta-9 THC
Clinical-stage pharmaceutical company SciSparc Ltd. announced that The Israeli Medical Center for Alzheimer’s has recruited the first patient for a clinical trial using the company’s proprietary cannabinoid-based technology. The subject will participate in the company’s Phase IIa clinical trial that will evaluate the safety, tolerability and efficacy of SciSparc’s SCI-110 in patients with Alzheimer’s…